EHA / 13th Congress / Satellite symposia
Satellite symposia
Many Satellite Symposia have been webcasted.
Please click here to go to the site where the Genzyme Satellite Symposium has been webcasted
Program at a glance June 12, 2008
|
Hall A2 |
Auditorium 1 | Auditorium 2 | Hall A3 |
08:00 - 10:00 |
|
MDS FoundationChanging the World of MDS Diagnosis and Classification: Challenges in Morphology |
Shire pharmaceuticalsPerspectives in MPDs: team insights with the patient in mind |
|
10:45 - 12:45 |
PRIME OncologyEmerging Therapies in Hematological Malignancies |
Bayer Schering PharmaProgressive Treatment: Raising the bar concepts in CLL and NHL |
Genzyme OncologyChallenges in the management of Acute Myeloid Leukaemia (AML) |
CelgeneExtending Survival Time in Multiple Myeloma: Optimal Treatment |
13:30 - 15:30 |
NovartisManagement of iron overload: New insights and long-term data |
F. HOFFMANN – LA ROCHE LTDRebuilding your patients’ lives |
Bristol-Myers SquibCML in the age of molecular medicine |
CELGENEChanging the Treatment Standards in MDS |
16:15 - 18:15 |
NOVARTISTKIs in CML: same target, new power Addressing the spectrum of BCR-ABL pathology |
ORTHO BIOTECHChallenging Unmet Medical Needs in Hematology Patients |
BRISTOL-MYERS SQUIBBShaping the future of CML management: Talking with the Experts |
CelgeneLenalidomide in haematological malignancies: from promise to practice |
|
Hall C1 |
Hall C3 | Hall C5 |
08:00 - 10:00 |
GLAXOSMITHKLINENew Insights into the burden of illness and treatment of idiopathic thrombocytopenic purpura (ITP) |
Physicians’ Education resourceOptimizing Strategies for Targeting CD20 in CLL and NHL |
MSD OncologyNew Therapeutic Targets in Hematological Malignancies |
10:45 - 12:45 |
NovartisNew targets – New agents for Hematologic Malignancies |
EpiCept CorporationRecent Advances in Induction and Post Remission in Acute Myeloid Leukemia |
Wyeth PharmaceuticalsNew Targets in Lymphoma Treatment |
13:30 - 15:30 |
MundipharmaWhich problems remain to be solved in haematologic malignancies? |
PharmacosmosIs it Possible to significantly Reduce the use of Blood Transfusions ? - Future Trends |
Boehringer IngelheimPrevention and treatment of venous thromboembolic disorders – Future needs |
16:15 - 18:15 |
AmgenChronic ITP: transforming treatment standards in 2008 |
Genzyme
Webcast |
Cephalon EuropeNew therapeutic approaches in AML patients: Raising the standards? |
Print view ]
